Follow the money

Companies trying to sell IPOs on U.S. markets are having a tough go at finding buyers. However, U.S. bioscience companies are having success selling equity to European investors.

Stateside, Genzyme Molecular postponed its NASDAQ IPO of 3 million shares at $9-$11, citing poor market conditions, and Collateral Therapeutics (Proposed:CLTX) reduced the proposed price range for its 3.33 million-share IPO to $8 from $11-$13. If Collateral sells the deal at $8, it would be valued at $46.4 million less than if the deal had gone at $12...